Impact of preexisting nucleos(t)ide reverse transcriptase inhibitor resistance on the effectiveness of bictegravir/emtricitabine/tenofovir alafenamide in treatment experience patients

INTRODUCTION: Few clinical trials and cohort studies have evaluated the efficacy of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in people with HIV (PWH) with preexisting M184V/I or other nucleos(t)ide reverse transcriptase inhibitor (NRTI) resistance-associated mutations (RAMs). Real-w...

Descripción completa

Detalles Bibliográficos
Autores principales: Micán, Rafael, de Gea Grela, Alejandro, Cadiñanos, Julen, de Miguel, Rosa, Busca, Carmen, Bernardino, Jose I., Valencia, Eulalia, Montes, Maria Luisa, Montejano, Rocío, Moreno, Victoria, Pérez Valero, Ignacio, Serrano, Lucía, González-García, Juan, Arribas, Jose R., Martín-Carbonero, Luz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Clinical Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9612675/
https://www.ncbi.nlm.nih.gov/pubmed/35848506
http://dx.doi.org/10.1097/QAD.0000000000003311

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9612675/
https://www.ncbi.nlm.nih.gov/pubmed/35848506
http://dx.doi.org/10.1097/QAD.0000000000003311

Ejemplares similares